ALEC,Alector, Inc. | Healthcare - www.financetom.com

Healthcare

ALEC

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Alector, Inc.ALEC

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.

Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases.

Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Latest News >

Optimism Around US Government Shutdown End, China Inflation Views Lift Asian Stock Markets

Nov 10, 2025

05:38 AM EST, 11/10/2025 (MT Newswires) -- Asian stock markets rose Monday following media reports that the US government shutdown may be nearing an end, and after relatively positive inflation reports from Beijing. Hong Kong, Shanghai and Tokyo finished in the green, as did most other regional exchanges. The South Korean KOSPI rose 3% on the US outlook, and hopes...

Merck's Phase 3 Trial of Enlicitide Decanoate in Heterozygous Familial Hypercholesterolemia Achieves Primary Endpoint

Nov 10, 2025

05:54 AM EST, 11/10/2025 (MT Newswires) -- Merck ( MRK ) said Sunday that a phase 3 study of its elicitide decanoate product candidate achieved its primary endpoint, demonstrating statistically significant reduction in low-density lipoprotein cholesterol, or LDL-C, in adult patients with heterozygous familial hypercholesterolemia. The company said enlicitide led to a clinically meaningful LDL-C reduction of 59.4% compared with...

Monroe Capital Supports Respida Capital’s Acquisition of ENTOUCH

Nov 10, 2025

CHICAGO--(BUSINESS WIRE)-- Monroe Capital LLC (“Monroe”) announced it led the growth capital investment to support the acquisition of ENTOUCH by Respida Capital. Founded in Dallas, Texas in 2008, ENTOUCH provides energy management as a service and smart building technology. The company’s cloud-based software delivers sustainable solutions that reduce energy usage, drive profitably, and simplify facility management for multisite operators. “We...

Cargojet Renews Normal Course Issuer Bid for Voting Shares

Nov 10, 2025

05:55 AM EST, 11/10/2025 (MT Newswires) -- Cargojet ( CGJTF ) , which rose 2.5% on Friday, later that day said it has received approval from the Toronto Stock Exchange to renew its normal course issuer bid for common voting shares and variable voting shares. The NCIB is scheduled to run from Nov. 11, 2025, to Nov. 10, 2026. Purchases...